Results 1 to 10 of about 184,499 (325)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2023
BACKGROUND Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is
R. K. Kelley, M. Ueno, C. Yoo, Richard S. Finn, J. Furuse, Z. Ren, T. Yau, H. Klümpen, S.L. Chan, M. Ozaka, C. Verslype, M. Bouattour, Joon-Oh Park, O. Barajas, U. Pelzer, J. Valle, Li Yu, U. Malhotra, A. Siegel, J. Edeline, A. Vogel   +20 more
exaly   +2 more sources

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Molecular Cancer, 2022
Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu, Wenjie Huang, Xianxing Wang, Junfeng Zhang, Tian Tao, Yao Zheng, Songsong Liu, Jiali Yang, Zhe-Sheng Chen, Chao-Yun Cai, Jinsui Li, Huaizhi Wang, Yingfang Fan   +12 more
doaj   +2 more sources

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Lancet, The, 2023
Summary Background Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for ...
Z. Wainberg, D. Melisi, T. Macarulla, R. P. Cid, S. Chandana, C. De, La Fouchardière, A. Dean, I. Kiss, Woo Jin, Thorsten O Lee, Eric Goetze, V. Cutsem, Scott Paulson, Tanios B. Bekaii-Saab, S. Pant, R. Hubner, Zhimin Xiao, Huanyu Chen, F. Benzaghou, E. O’Reilly, Chen, David Geffen   +22 more
exaly   +2 more sources

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Lancet, The, 2017
BACKGROUND The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
John Neoptolemos, Juan Valle, Christopher M Halloran   +2 more
exaly   +2 more sources

Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis [PDF]

Journal of International Medical Research
Objective Gemcitabine plus cisplatin is the standard adjuvant regimen for postoperative management of muscle-invasive upper tract urothelial carcinoma. This study investigated whether adding tislelizumab to gemcitabine plus cisplatin improves outcomes in
Jingwen Zhang, Yongshuang Xiao, Donghua Cai, Hua Zhu, Wei Zhong   +4 more
doaj   +2 more sources

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

New England Journal of Medicine, 2018
BACKGROUND Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy.
Thierry Conroy, Alice C Wei, Thierry Lecomte   +2 more
exaly   +2 more sources

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Journal of Experimental & Clinical Cancer Research, 2023
Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao, Yabin Yu   +8 more
doaj   +2 more sources

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

New England Journal of Medicine, 2019
BACKGROUND Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.
Yuan Zhang, Ning Zhang, Mei Shi
exaly   +2 more sources

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Lancet, The, 2021
BACKGROUND The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.
Stephanie Lheureux, Tracy Stockley, Prisni Rath   +2 more
exaly   +2 more sources

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

Cell Metabolism, 2019
Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant infiltration of tumor-associated macrophages (TAMs). TAMs have been reported to drive resistance to gemcitabine, a frontline chemotherapy in PDA, though the mechanism of this resistance ...
Christopher J Halbrook, Ilya Kovalenko, Ho-Joon Lee   +2 more
exaly   +2 more sources